#USA #San Francisco #organ preservation #Hope #Bridge to Life™

Bridge to Life™ at the 2025 World Transplant Congress

Bridge to Life™ Ltd., a frontrunner in organ preservation and perfusion technology, is preparing to make waves at the upcoming 2025 World Transplant Congress (WTC), scheduled for August 2-6 in San Francisco. With a wealth of data from a pivotal 12-month clinical study on hypothermic oxygenated perfusion (HOPE), the company is set to highlight significant findings that could reshape practices in organ transplantation.

Key Presentations and Discussions

The pivotal study titled Bridge to HOPE will be a focal point of the conference, showcasing not only the clinical efficacy of HOPE in liver transplants but also its economic impacts. Dr. Chase J. Wehrle from the Cleveland Clinic will lead a plenary session detailing a post-hoc analysis of the randomized study, comparing it with institutional data. This session is a must-attend, particularly since Dr. Wehrle is being honored with the ILTS 2025 Young Investigators Award.

Additional poster presentations will cover critical insights such as:

• - The effects of hypothermic oxygenated machine perfusion on ischemia-reperfusion injury in liver transplants, with differing analyses based on donor age, presented by Dr. Marco Maria Pascale from Italy.
• - Mitochondrial damage and function comparisons between the two machine perfusion methods, a cornerstone analysis by Dr. Omer Faruk Karakaya from the Cleveland Clinic.

Oral Abstract Presentations

Researchers will also present groundbreaking findings through oral abstracts:

• - An economic evaluation of hypothermic oxygenated machine perfusion on August 5, presented by Dr. David Axelrod from the University Hospitals Cleveland Medical Center.
• - Another session will illustrate a reduced severity of rejection correlating with hypothermic oxygenated perfusion findings, revealing compelling data from a large-scale pivotal study for liver transplants, again delivered by Dr. David J. Reich from Drexel University on August 6.

Late-Breaking Presentations

On the first day of the conference, there will be a series of late-breaking oral abstracts discussing innovations in evaluating the viability of split liver transplants, utilizing hypothermic oxygenated perfusion technologies.

Symposium on HOPE

Bridge to Life™ will sponsor an early morning symposium titled "Hypothermic Oxygenated Perfusion (HOPE): From Science to Clinical Impact" on August 4, featuring discussions led by experts like Dr. David Axelrod and Dr. Andrea Schlegel. This will be an excellent opportunity for attendees to understand the scientific breakthroughs and their practical implications in transplantation.

Company Background

Founded with a commitment to revolutionizing organ preservation, Bridge to Life™ Ltd. offers groundbreaking products, including Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. The company prides itself on innovation and accessibility, partnering with top transplantation centers globally while maintaining a strong focus on product excellence.

VitaSmart™ is notable for being CE-marked and available in several international markets, although FDA approval in the U.S. is still pending.

Bridge to Life™’s presence at WTC 2025 underscores its vital role in advancing transplantation science, potentially leading to better outcomes for transplant recipients around the world. Attendees are encouraged to participate actively in discussions and presentations to fully grasp the future of organ preservation technology.